TC Biopharm (Holdings) Plc (TCBP) News & Overview - Discounting Cash Flows
TCBP
TC Biopharm (Holdings) Plc
TCBP (NASDAQ)

TCBP's Business Model

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Sector & Industry Healthcare / Biotechnology
Website https://www.tcbiopharm.com
CEO (Chief Executive Officer) Bryan Leland Kobel
Number of Employees
IPO date February 11, 2022

TCBP Latest News

Contact
CountryGB
AddressMaxim 1
CityMotherwell
StateNone
Phone44 14 1433 7557
Zip CodeML1 4WR
Other Identifiers
CIK0001872812
ISINUS87807D4007
CUSIP87807D103
Open1.51
Previous Close0.5
Volume5.9 Mil.
Average Volume377.7 Thou.
Day’s Range0.5 – 1.51
52 Week Range0.08-523.2
MA (50)3.18346
MA (200)48.27303
Market Cap256.5 Thou.
Shares Out.513 Thou.
Earnings DateFeb 26, 2025
Beta
Last Dividend
EPS
PE

Industry Competitors for TCBP

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us